Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans
MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India
More from Archive
More from Scrip
• By
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
• By
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.